CLINICAL_TRIALS
withdrawal
· 2025-06-27
Clinical Trial Update: An Exploratory Clinical Study of GC012F Injection for Refractory gMG [EARLY_Phase 1]
Summary
An exploratory early-phase study evaluating GC012F injection for refractory generalized myasthenia gravis has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Zhejiang University | Conditions: Refractory Generalized Myasthenia Gravis | EARLY_Phase 1 | Status: WITHDRAWN